Tesla, Inc.

• MEDTotal stock-based compensation was $2.825B in 2025, up 41% from $1.999B in 2024 S7. Unrecognized SBC on non-performance awards alone is $5.82B, with a 2.6-year weighted average recognition period S7. Dilutive stock-based awards in the share count grew from 298 million (2023) to 303 million shares (2025) S6. On top of this, $1.79B in additional performance-based grants across 13.0 million shares remains unrecognized S7. SBC at $2.83B represents approximately 3% of revenue S4S7, which is elevated for a company of this scale and revenue trajectory.

Nothing flagged.

• LOWTotal debt and finance leases are $8.376B, with $1.64B current and $1.58B due in 2026, and $4.39B due in 2029 S5S6. Against $16.51B in cash S6 and $6.43B in unused committed credit S4, near-term maturities are manageable. The company is in material compliance with all debt covenants as of December 31, 2025 S6. Debt covenants do restrict ability to incur additional debt and require maintenance of certain liquidity levels S3.

• MEDChina represented $20.96B of total revenues of $94.83B (approximately 22%) S7. The company manufactures in Shanghai (Gigafactory Shanghai, described as in a flood-prone area) S3 and is subject to escalating U.S.-China trade policy risk, retaliatory tariffs, and China-specific regulatory requirements. Tariff policy changes in 2025 have already impacted supply chain costs, with larger effects on the energy business S4.
• MEDBattery cell supply is dependent on a limited number of qualified suppliers, specifically Panasonic and CATL, with the filing stating there is "no flexibility in changing suppliers" S2. Some components are single-sourced S2. A disruption at either battery supplier would directly constrain vehicle and energy product output.

• HIGHCEO Elon Musk received a restricted stock award in August 2025 with a grant date fair value of $26.06 billion S7, plus a September 2025 performance award covering 423.7 million shares with market cap milestones ranging from $2.0T to $8.5T S7. Unrecognized stock-based compensation tied to that performance award ranges from $10.23B (probable milestones) to $120.37B (all milestones) S5S7. The A&R 2019 Plan created a special reserve of approximately 208 million shares just for the CEO S6. No expense was recorded on the interim award as of December 31, 2025 because vesting is deemed not probable S7, but if milestones are hit, dilution to existing shareholders would be enormous. Musk also does not devote full time to Tesla, simultaneously managing SpaceX, xAI, Neuralink, and The Boring Company S3.
• HIGHMusk's personal bank borrowings are secured by pledged Tesla common stock S3. A sharp stock price decline could force involuntary sales of large share blocks into the market, accelerating any selloff. The 52-week trading range was $214.25 to $498.83 S3, a spread of more than 2x, illustrating how quickly that trigger could become relevant.
• MEDThe company discloses it is "cooperating with unspecified government investigations" with potential for liability, penalties, and restrictive sanctions S3. No details are provided on the nature, scope, or timeline of these investigations. The lack of specificity prevents investors from sizing the risk.
• LOWBitcoin holdings of

Nothing flagged.

• HIGHCore automotive revenue fell 9% year-over-year to $65.82B in 2025 S4, driven by an 8% decline in cash deliveries and lower average selling prices from mix shift and higher customer incentives S4. Total company revenue declined $2.86B (3%) to $94.83B S4, and net income fell 46% year-over-year from $7.09B to $3.79B S6. The automotive business is contracting in both volume and price simultaneously.
• HIGHCapEx is expected to exceed $20 billion in 2026 S4, more than double the $8.53B spent in 2025 S4. Free cash flow in 2025 was approximately $6.22B ($14.75B operating cash flow minus $8.53B CapEx) S4. If 2026 CapEx hits $20B against similar operating cash flow, free cash flow turns sharply negative or near zero, forcing reliance on the $16.51B cash balance S6 or new financing. AI infrastructure CapEx alone grew 33% year-over-year to $6.82B gross in 2025 S6, and construction in progress stands at $8.79B S6.
• MEDThe automotive warranty reserve surged 28% year-over-year from $6.72B to $8.61B S6. Warranty expense grew 19% year-over-year to $1.72B in 2025 S6. Auditors designated the automotive warranty reserve as a critical audit matter, citing significant management judgment required in estimating future claim frequency and cost, particularly for certain vehicle models S5. Inventory write-downs also increased 63% year-over-year to $310M in 2025 from $190M in 2024 S6, pointing to demand or obsolescence pressure.
• MEDR&D expense jumped 41% year-over-year to $6.41B in 2025 (7% of revenue, up from 5%) S4, with $500 million of that increase attributable to stock-based compensation alone S4. The bulk of this spending is on AI, autonomy, and Optimus, none of which generate meaningful revenue today. The Robotaxi service launched in June 2025 but relies on regulatory approval that remains fragmented across U.S. states, EU member states, and China S2S3. If these bets do not generate returns, the R&D ramp represents sustained margin pressure with no offsetting revenue.
• MEDResale value guarantee exposure nearly doubled from $1.45B (2024) to $3.45B (2025) S5. If used vehicle values fall (as they have broadly in the EV market), Tesla could be forced to absorb resale losses at scale on this growing guarantee book.

• HIGHThe One Big Beautiful Bill Act (OBBBA), enacted July 4, 2025, repealed individual consumer EV tax credits, repealed residential energy property credits, and imposed accelerated phase-outs on commercial solar credits (expiring after December 31, 2027) S2. Automotive regulatory credit revenue fell 28% year-over-year to $1.99B in 2025 directly because of these restrictions S4S5. Regulatory credits are nearly pure profit (no associated cost of goods), so this decline hits gross margin disproportionately hard. The filing states OBBBA is expected to "materially affect" consolidated financials S6.

• MEDIn August 2025, a jury awarded $129M in compensatory damages plus $200M in punitive damages against Tesla in the Benavides product liability case S7. Tesla filed post-trial motions and recorded only an immaterial accrual S7. A class action covering California consumers for FSD/Autopilot claims was certified in August 2025; Tesla appealed and the case is stayed pending that appeal S7. A securities class action was filed in the Western District of Texas in August 2025 alleging Autopilot-related misrepresentations S7. The aggregate exposure across these cases is not fully quantified in the filing.

• MEDThe effective tax rate increased to 27.0% in 2025 from 20% in 2024 S4S7, driven by jurisdictional earnings mix, OBBBA impact on deductions, and NCTI remeasurement S4. Unrecognized tax benefits grew to $1.746B from $1.417B S7. The valuation allowance increased by $541M to $1.77B in 2025 S7, suggesting reduced confidence in utilizing deferred tax assets. Approximately $371M in unrecognized withholding tax liability sits on indefinitely reinvested foreign earnings S7.